United Therapeutics Corporation is a biotechnology firm focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases. The company develops technology platforms for prostacyclin analogs, immunotherapeutic monoclonal antibodies, glycobiology and telemedicine. It performs activities for cardiovascular health, including the development of analogs of the endogenous hormone prostacyclin for the treatment of pulmonary arterial hypertension and critical limb ischemia. United Therapeutics telemedicine services are focused on patients with an array of possible cardiac arrhythmias. The company s IMA therapies are designed to combat ovarian, prostate, breast, lung, pancreatic and colorectal cancers. Its glycobiology compounds target hepatitis C and other infectious diseases. United Therapeutics strategy is balanced among mature programs, pivotal development and early-stage pipeline activities. The company is headquartered in Silver Spring, Md.